INPHASOL INC.

Biotech · Private

Orally administered therapeutic to reduce hydrogen sulfide production by sulfate-reducing bacteria in the gut microbiome

Grants
$178K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Phagineering the gut microbiome: Bacteriophages to reduce Desulfovibrio spp. and hydrogen sulfide in the intestine$178,026
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2270Lilac Therapeutics——
2271IMMUNYX PHARMA USA INC.——
2272CISTERNA BIOLOGICS, INC.——
2273INPHASOL INC.——
2274SYNVEST IMAGING INC.——
2275EdenRoc Sciences LLC—$194M
2276ENGAGE BIOLOGICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.